SCHEMBL2312296

SCHEMBL2312296

O=C(O)c1csc2c(NC3CC3)ncnc12

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.48
ERN1 O75460 3/20 0.44
BRAF P15056 3/20 0.44
IRAK4 Q9NWZ3 2/20 0.40
CHRM4 P08173 3/20 0.40
CYP3A4 P08684 2/20 0.40
CSNK2A1 P68400 1/20 0.39
AURKA O14965 1/20 0.39
RPS6KB1 P23443 1/20 0.39
HCAR3 P49019 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
ADORA1 P30542 1/20 0.38
BTK Q06187 4/20 0.38
CD38 P28907 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9931092 0.91 RPS6KB1 (0.51) MAPTERN1BRAFAURKARPS6KB1
SCHEMBL9931440 0.91 JAK2 (0.46) MAPTERN1BRAFIRAK4CHRM4
SCHEMBL9931421 0.89 MAPT (0.43) MAPTERN1BRAFIRAK4CHRM4
SCHEMBL9931348 0.88 MAPT (0.41) MAPTERN1BRAFIRAK4CHRM4
SCHEMBL9931256 0.86 ADORA1 (0.41) MAPTERN1BRAFADORA3ADORA1
SCHEMBL9930629 0.86 MAPT (0.44) MAPTERN1BRAFIRAK4RPS6KB1
SCHEMBL9930225 0.86 CHRM4 (0.43) MAPTERN1BRAFCHRM4AURKA
SCHEMBL9930988 0.80 AURKA (0.43) MAPTERN1BRAFAURKARPS6KB1
SCHEMBL29116263 0.80 MAPT (0.65) MAPTIRAK4CHRM4CYP3A4CYP2C9
SCHEMBL9930841 0.80 YTHDC1 (0.35) MAPTBRAFCSNK2A1HCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3617213-B1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARMACEUTICAL CO LTD (KR) 2025-02-19 EP disclosed
EP-3617213-A1 THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES Hanmi Pharm. Co., Ltd. (KR) 2020-03-04 EP disclosed
EP-2797927-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM IND CO LTD (KR) 2019-09-25 EP disclosed
US-RE47451-E1 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO. LTD. (KR) 2019-06-25 US disclosed
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP disclosed
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP disclosed
US-9156852-B2 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM. CO., LTD (KR) 2015-10-13 US disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
CN-104039798-A Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases HANMI PHARM IND CO LTD 2014-09-10 CN disclosed
WO-2013100632-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES HANMI PHARM CO., LTD. (KR) 2013-07-04 WO disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
EP-2528925-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES Hanmi Science Co., Ltd. (KR) 2012-12-05 EP disclosed
EP-2470538-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2012-07-04 EP disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed
WO-2011093684-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI HOLDINGS CO., LTD. (KR) 2011-08-04 WO disclosed
WO-2011093684-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI HOLDINGS CO., LTD. (KR) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF MAPT 1082/4885ERN1 185/4885BRAF 1/4885
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES CDK2, TK1, DTYMK MAPT 1324/4885ERN1 756/4885BRAF 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.